Zobrazeno 1 - 10
of 664
pro vyhledávání: ''
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2022)
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2022)
Background and aims: Xuanfei Baidu decoction (XFBD), a traditional Chinese medicine formulation, was designed and successfully applied for COVID-19 disease treatment in China, while the mechanism is still not clear.Methods: To evaluate the protective
Autor:
Bin Zhang, Yanling Zhou, Hai-Shan Shi, Xiaofeng Lan, Yuping Ning, Wei Zheng, Chengyu Wang, Li-Mei Gu, Dan-Feng Wang
Publikováno v:
Frontiers in Psychiatry, Vol 12 (2021)
Frontiers in Psychiatry
Frontiers in Psychiatry
Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD).Methods: Seventy-eight patients with
Autor:
Mengli Xu, Andrea Wang-Gillam, Dao Xin, Shanggang Zong, Yao Lu, Feng Wang, Li Wang, Yuanyuan Yang, Lulu Guan, Yalan Yang, Yu Chen
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
PurposeTo characterize the mechanism by which metformin inhibits PD-L1 expression in esophageal squamous cell carcinoma (ESCC) and to evaluate the effect of metformin on the antitumor immune response.MethodsThe Cancer Genome Atlas (TCGA) database was
Autor:
Fang Liu, Bo-Ning Cai, Xiaomo Li, Jing Chen, Wei Yang, Wei Yu, Xiang Huang, Baolin Qu, Pei Zhang, Tonghui Ma
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for advanced non-small-cell lung cancer (NSCLC) patients. However, most patients will eventually develop resistance. For EGFR-TKI resistance mediated b
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundAdvanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations has been successfully treated with tyrosine kinase inhibitors (TKIs). However, resistance to osimertinib, a third-generation TKI, can be
Autor:
Jun Ikezawa, Fusako Yokochi, Ryoichi Okiyama, Satoko Kumada, Maya Tojima, Tsutomu Kamiyama, Takashi Hanakawa, Hiroshi Matsuda, Fumiaki Tanaka, Yasuhiro Nakata, Eiji Isozaki
Publikováno v:
Frontiers in Neurology
Frontiers in Neurology, Vol 12 (2021)
Frontiers in Neurology, Vol 12 (2021)
Background: The pathogenesis of dystonia is remarkably diverse. Some types of dystonia, such as DYT5 (DYT-GCH1) and tardive dystonia, are related to dysfunction of the dopaminergic system. Furthermore, on pathological examination, cell loss in the su
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on col
Publikováno v:
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Background: Non-dipper hypertension is often characterized by a blunted decrease of nocturnal blood pressure (BP) and is associated with increased risk of target organ damage and cardiovascular (CV) events, while the optimal treatment strategy is yet
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Objectives: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Kalydeco® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and Symkevi® (tezacaftor/ivacaftor), have substantially improved patients’ lives yet significantly burden h
Autor:
Hanqi Lu, Yanting You, Xinghong Zhou, Qiuxing He, Ming Wang, Liqian Chen, Lin Zhou, Xiaomin Sun, Yanyan Liu, Pingping Jiang, Jiaojiao Dai, Xiuqiong Fu, Hiu Yee Kwan, Xiaoshan Zhao, Linjie Lou
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
BackgroundStudies have shown that gut microbe disorder in mice due to early-life antibiotic exposure promotes glycolipid metabolism disorder in adulthood. However, the underlying mechanism remains unclear and there is not yet an effective interventio